286 related articles for article (PubMed ID: 24489747)
1. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics.
Alistar SS; Owens DK; Brandeau ML
PLoS One; 2014; 9(1):e86584. PubMed ID: 24489747
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.
Alistar SS; Owens DK; Brandeau ML
PLoS Med; 2011 Mar; 8(3):e1000423. PubMed ID: 21390264
[TBL] [Abstract][Full Text] [Related]
3. Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.
Bernard CL; Owens DK; Goldhaber-Fiebert JD; Brandeau ML
PLoS Med; 2017 May; 14(5):e1002312. PubMed ID: 28542184
[TBL] [Abstract][Full Text] [Related]
4. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
Long EF; Stavert RR
J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
[TBL] [Abstract][Full Text] [Related]
5. Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study.
Uyei J; Fiellin DA; Buchelli M; Rodriguez-Santana R; Braithwaite RS
Lancet Public Health; 2017 Mar; 2(3):e133-e140. PubMed ID: 29253386
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of alternative strategies for provision of HIV preexposure prophylaxis for people who inject drugs.
Fu R; Owens DK; Brandeau ML
AIDS; 2018 Mar; 32(5):663-672. PubMed ID: 29334549
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam's injection-driven HIV epidemics.
Tran BX; Ohinmaa A; Duong AT; Nguyen LT; Vu PX; Mills S; Houston S; Jacobs P
Drug Alcohol Depend; 2012 Oct; 125(3):260-6. PubMed ID: 22436971
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK
AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study.
Choi H; Suh J; Lee W; Kim JH; Kim JH; Seong H; Ahn JY; Jeong SJ; Ku NS; Park YS; Yeom JS; Kim C; Kwon HD; Smith DM; Lee J; Choi JY
Sci Rep; 2020 Sep; 10(1):14609. PubMed ID: 32884082
[TBL] [Abstract][Full Text] [Related]
10. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
Alistar SS; Grant PM; Bendavid E
BMC Med; 2014 Mar; 12():46. PubMed ID: 24629217
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and cost-effectiveness of early antiretroviral therapy and partners' pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study.
Hu QH; Meyers K; Xu JJ; Chu ZX; Zhang J; Ding HB; Han XX; Jiang YJ; Geng WQ; Shang H
BMC Infect Dis; 2019 Jul; 19(1):663. PubMed ID: 31345169
[TBL] [Abstract][Full Text] [Related]
13. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of methadone maintenance treatment for HIV-positive drug users in Vietnam.
Tran BX; Ohinmaa A; Duong AT; Do NT; Nguyen LT; Mills S; Houston S; Jacobs P
AIDS Care; 2012; 24(3):283-90. PubMed ID: 21936718
[TBL] [Abstract][Full Text] [Related]
15. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies.
Gomez GB; Borquez A; Case KK; Wheelock A; Vassall A; Hankins C
PLoS Med; 2013; 10(3):e1001401. PubMed ID: 23554579
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
[TBL] [Abstract][Full Text] [Related]
17. Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities.
Krebs E; Zang X; Enns B; Min JE; Behrends CN; Del Rio C; Dombrowski JC; Feaster DJ; Gebo KA; Marshall BDL; Mehta SH; Metsch LR; Pandya A; Schackman BR; Strathdee SA; Nosyk B;
J Infect Dis; 2020 Sep; 222(Suppl 5):S301-S311. PubMed ID: 32877548
[TBL] [Abstract][Full Text] [Related]
18. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.
Li J; Peng L; Gilmour S; Gu J; Ruan Y; Zou H; Hao C; Hao Y; Lau JT
BMC Infect Dis; 2018 Nov; 18(1):600. PubMed ID: 30486800
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of oral pre-exposure prophylaxis and expanded antiretroviral therapy for preventing HIV infections in the presence of drug resistance among men who have sex with men in China: A mathematical modelling study.
Jin X; Shi L; Wang C; Qiu T; Yin Y; Shen M; Fu G; Peng Z
Lancet Reg Health West Pac; 2022 Jun; 23():100462. PubMed ID: 35542892
[TBL] [Abstract][Full Text] [Related]
20. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand.
Suraratdecha C; Stuart RM; Manopaiboon C; Green D; Lertpiriyasuwat C; Wilson DP; Pavaputanon P; Visavakum P; Monkongdee P; Khawcharoenporn T; Tharee P; Kittinunvorakoon C; Martin M
J Int AIDS Soc; 2018 Jul; 21 Suppl 5(Suppl Suppl 5):e25129. PubMed ID: 30033559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
